SHANGHAI – Beijing-based Canbridge Life Sciences Inc. is a biotech that seeks to bring Western innovation to Chinese patients who have few if any treatment options. That licensing strategy has led it to sign a deal with Apogenix GmbH, of Heidelberg, Germany, for lead candidate APG101, an onco-immunotherapy targeting the CD95 ligand for a highly lethal and difficult to treat type of brain cancer, glioblastoma multiforme. Read More

Nanocell firm Engeneic Ltd. started using cancer immunotherapy in its unique way "before anyone else, because we have bacterially derived particles," Managing Director Jennifer MacDiarmid told BioWorld Asia. Read More

SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., a billion-dollar integrated pharma with R&D centers in New Jersey, Shanghai and Chengdu, has been pushing in the direction of innovation faster and farther than most other Chinese pharmas. And with the recent announcement they will invest ¥850 million (US$137 million) in a biologics manufacturing plant, it's clear the execs aren't afraid to invest heavily in the high-risk area of large molecules and immunotherapy. Read More

SHANGHAI – Phagelux Inc., a Shanghai-based company developing bacteriophages for both human and animal use, has acquired Omnilytics Inc. as part of a mission to leverage phage technology in the battle against antibiotic overuse. Read More

Lorati Co. Ltd., of Taipei, Taiwan, said it has developed a nano-medication that can effectively inhibit HIV-1 viral replication. The company said the nano-medication, based on bentonite, can yield improvement within one month of treatment. Read More